Keros Therapeutics (NASDAQ: KROS) reported Q3 EPS of ($0.18), $0.87 better than the analyst estimate of ($1.05). Revenue for the quarter came in at $14.26 million versus the consensus estimate of $6.33 million.

For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.